Terms: = Prostate cancer AND KIT, C-Kit, 3815, ENSG00000157404, CD117, SCFR, P10721 AND Treatment
222 results:
1. A metabolomics approach reveals metabolic disturbance of human cholangiocarcinoma cells after parthenolide treatment.
He Y; Yu Q; Ma X; Lv D; Wang H; Qiu W; Chen XF; Jiao Y; Liu Y
J Ethnopharmacol; 2024 Jun; 328():118075. PubMed ID: 38513779
[TBL] [Abstract] [Full Text] [Related]
2. Curcumin Enhances the Anti-cancer Efficacy of CDK4/6 Inhibitors in prostate cancer.
Zhao H; Ding R; Han J
Arch Esp Urol; 2024 Jan; 77(1):57-66. PubMed ID: 38374014
[TBL] [Abstract] [Full Text] [Related]
3. High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor.
Wang F; Zhang G; Xu T; Ma J; Wang J; Liu S; Tang Y; Jin S; Li J; Xing N
J Exp Clin Cancer Res; 2024 Jan; 43(1):24. PubMed ID: 38245792
[TBL] [Abstract] [Full Text] [Related]
4. Serine/threonine kinase 36 induced epithelial-mesenchymal transition promotes docetaxel resistance in prostate cancer.
He T; Li NX; Pan ZJ; Zou ZH; Chen JC; Yu SZ; Lv F; Xie QC; Zou J
Sci Rep; 2024 Jan; 14(1):729. PubMed ID: 38184689
[TBL] [Abstract] [Full Text] [Related]
5. ADP-dependent glucokinase controls metabolic fitness in prostate cancer progression.
Xu H; Li YF; Yi XY; Zheng XN; Yang Y; Wang Y; Liao DZ; Zhang JP; Tan P; Xiong XY; Jin X; Gong LN; Qiu S; Cao DH; Li H; Wei Q; Yang L; Ai JZ
Mil Med Res; 2023 Dec; 10(1):64. PubMed ID: 38082365
[TBL] [Abstract] [Full Text] [Related]
6. Polyphyllin I induces ferroptosis in castration-resistant prostate cancer cells through the ERK/DNMT1/ACSL4 axis.
Zou P; Chen Z; He Q; Zhuo Y
Prostate; 2024 Jan; 84(1):64-73. PubMed ID: 37750290
[TBL] [Abstract] [Full Text] [Related]
7. Berbamine Inhibits the Biological Activities of prostate cancer Cells by Modulating the ROS/NF-κB Axis.
Zhao W; Jiang Y; Jia X; Wang X; Guo Y
Anticancer Agents Med Chem; 2023; 23(14):1626-1633. PubMed ID: 37638593
[TBL] [Abstract] [Full Text] [Related]
8. PSMC4 promotes prostate carcinoma progression by regulating the CBX3-EGFR-PI3K-AKT-mTOR pathway.
Liu K; Zhang S; Gong Y; Zhu P; Shen W; Zhang Q
J Cell Mol Med; 2023 Aug; 27(16):2437-2447. PubMed ID: 37436074
[TBL] [Abstract] [Full Text] [Related]
9. Gleason Score-related MT1L as biomarker for prognosis in prostate adenocarcinoma and contribute to tumor progression in vitro.
Liu L; Li Y; Tang S; Yang B; Zhang Q; Xiao R; Hou X; Liu C; Ma L
Int J Biol Markers; 2023 Jun; 38(2):114-123. PubMed ID: 37192745
[TBL] [Abstract] [Full Text] [Related]
10. Combination of Urinary MiR-501 and MiR-335 With Current Clinical Diagnostic Parameters as Potential Predictive Factors of prostate Biopsy Outcome.
Juracek J; Madrzyk M; Trachtova K; Ruckova M; Bohosova J; Barth DA; Pichler M; Stanik M; Slaby O
Cancer Genomics Proteomics; 2023; 20(3):308-316. PubMed ID: 37093688
[TBL] [Abstract] [Full Text] [Related]
11. Silencing LINC00491 inhibits prostate cancer development through the miR-384/TRIM44 axis.
Zhou S; Wu C; Tang Q; Zhou X; He B; Chang P; He X
J Biochem Mol Toxicol; 2023 Jul; 37(7):e23370. PubMed ID: 37070216
[TBL] [Abstract] [Full Text] [Related]
12. P-score in preoperative biopsies accurately predicts P-score in final pathology at radical prostatectomy in patients with localized prostate cancer.
Röbeck P; Xu L; Ahmed D; Dragomir A; Dahlman P; Häggman M; Ladjevardi S
Prostate; 2023 Jun; 83(9):831-839. PubMed ID: 36938873
[TBL] [Abstract] [Full Text] [Related]
13. Human C1q Tumor Necrosis Factor 8 (CTRP8) defines a novel tryptase+ mast cell subpopulation in the prostate cancer microenvironment.
Krishnan SN; Thanasupawat T; Arreza L; Wong GW; Sfanos K; Trock B; Arock M; Shah GG; Glogowska A; Ghavami S; Hombach-Klonisch S; Klonisch T
Biochim Biophys Acta Mol Basis Dis; 2023 Jun; 1869(5):166681. PubMed ID: 36921737
[TBL] [Abstract] [Full Text] [Related]
14. Phytochemical Analysis and Profiling of Antitumor Compounds of Leaves and Stems of
Youssef AMM; Maaty DAM; Al-Saraireh YM
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677687
[TBL] [Abstract] [Full Text] [Related]
15. Qi Ling decoction enhances abiraterone treatment via suppression of autophagy in castration resistant prostate cancer.
Feng Y; Cao H; Song Z; Chen L; Wang D; Gao R
Aging (Albany NY); 2022 Dec; 14(24):9942-9950. PubMed ID: 36541904
[TBL] [Abstract] [Full Text] [Related]
16. N
Chen B; Liu C; Long H; Bai G; Zhu Y; Xu H
Int J Oncol; 2023 Jan; 62(1):. PubMed ID: 36484368
[TBL] [Abstract] [Full Text] [Related]
17. Radiomic-based machine learning model for the accurate prediction of prostate cancer risk stratification.
Shu X; Liu Y; Qiao X; Ai G; Liu L; Liao J; Deng Z; He X
Br J Radiol; 2023 Mar; 96(1143):20220238. PubMed ID: 36475858
[TBL] [Abstract] [Full Text] [Related]
18. Ulinastatin ameliorates the malignant progression of prostate cancer cells by blocking the RhoA/ROCK/NLRP3 pathway.
Liu Z; Zhu X; Xu C; Min F; Yu G; Chen C
Drug Dev Res; 2023 Feb; 84(1):36-44. PubMed ID: 36461611
[TBL] [Abstract] [Full Text] [Related]
19. Targeting mTOR Complex 2 in Castration-Resistant prostate cancer with Acquired Docetaxel Resistance.
Huang Y; Zhai Y; Wu M; Chang C; Luo J; Hong D; Zhao Q; Dai Y; Liu J
Drug Des Devel Ther; 2022; 16():3817-3828. PubMed ID: 36388085
[TBL] [Abstract] [Full Text] [Related]
20. [
Maurin M; Wyczółkowska M; Sawicka A; Sikora AE; Karczmarczyk U; Janota B; Radzik M; Kłudkiewicz D; Pijarowska-Kruszyna J; Jaroń A; Wojdowska W; Garnuszek P
Molecules; 2022 Oct; 27(21):. PubMed ID: 36364046
[TBL] [Abstract] [Full Text] [Related]
[Next]
